Abstract
The action of kainic acid (KA), quisqualic acid (QA), and 1-(4-chlorobenzoyl)-piperazine-2,3-dicarboxylic acid (pCB-PzDA) was investigated in the central nervous system of male Sprague Dawley rats. Intracerebroventricularly injected KA and QA (100 nmol) induced spike discharges, and pCB-PzDA (100 nmol) suppressed electrocorticograms for one hour. pCB-PzDA enhanced the KA-induced spike discharges and inhibited those induced by QA. 2,3-Di-hydroxyphenylacetic acid(DOPAC) and homovanillic acid (HVA) levels were increased transiently by 10 nmol and continuously by 100 nmol of KA. KA dose-dependently increased 5-hydroxyindoleacetic acid (5-HIAA) levels 2 hours after administration. While 10 nmol of QA slightly increased the HVA level, 100 nmol of QA significantly increased DOPAC, HVA, and 5-HIAA levels. DOPAC and HVA levels were increased by 100 nmol of pCB-PzDA, although this agent inhibited KA-induced increases in DOPAC, HVA, and 5-HIAA levels. On the other hand, while pCB-PzDA first inhibited QA-induced increases in DOPAC, HVA and 5-HIAA levels for one hour, DOPAC and HVA levels thereafter increased additively. These findings suggest that pCB-PzDA may act not only as a NMDA antagonist, but that it may also act directly on dopamine...Continue Reading
References
Nov 24, 1978·Brain Research·P J Roberts, N A Sharif
May 1, 1979·Journal of Neurochemistry·P J Roberts, S D Anderson
Mar 24, 1977·Nature·I DivacJ Storm-Mathisen
Jun 10, 1977·Brain Research·P L McGeerK Singh
Nov 1, 1990·Neuroscience Research·T Tsumoto
Nov 1, 1989·Neurochemical Research·H KabutoA Mori
Apr 15, 1985·Biochemical Pharmacology·J W Commissiong
Sep 10, 1986·Brain Research·E W HarrisC W Cotman
Feb 1, 1987·Neuropharmacology·S M JonesK M Johnson
Jun 1, 1988·Neuropharmacology·R C Boldry, N J Uretsky
Oct 1, 1988·British Journal of Pharmacology·E J FletcherT Honoré
Feb 1, 1986·Biochemical Pharmacology·H AnandJ F Collins
Jan 14, 1987·Neuroscience Letters·L TurskiJ C Watkins
Jun 7, 1988·Brain Research·K Niijima, M Yoshida
Apr 13, 1988·European Journal of Pharmacology·T ZetterströmU Ungerstedt
Jun 30, 1986·Life Sciences·L A PhebusR W Fuller
Apr 19, 1985·Neuroscience Letters·A G ChapmanJ C Watkins
Aug 16, 1985·Neuroscience Letters·H FukudaY Yonemasu
May 23, 1985·Neuroscience Letters·A C MichaelD B Neill
Jan 1, 1981·Annual Review of Pharmacology and Toxicology·J C Watkins, R H Evans
Aug 1, 1983·Neuropharmacology·B A Donzanti, N J Uretsky
Sep 24, 1982·European Journal of Pharmacology·S J Czuczwar, B Meldrum
May 21, 1982·Science·M J CroucherB S Meldrum
Oct 1, 1977·Neuroscience Letters·M F GiorguieffJ Glowinski
Citations
Feb 28, 2001·European Journal of Pharmacology·J A BourneJ Halliday
Aug 6, 2000·Pathophysiology : the Official Journal of the International Society for Pathophysiology·I YokoiA Mori
Jul 5, 2011·Progress in Neurobiology·Antonio DragoAlessandro Serretti
Jul 1, 1997·British Journal of Pharmacology·A OzaitaJ A García-Sevilla